Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
What to Expect During the Transition Discontinuing GLP-1 therapy is not associated with severe addiction-like withdrawal
Energetics: i
Mol Metab (2021) 49:101181
Drug developers extended duration
Both of these medications are known for causing gastrointestinal (GI) side effects